World Health Organisation launches 4th edition of Classification of Skin Tumours
31 August 2018
The World Health Organisation (WHO) is releasing the 4th edition of Classification of Skin Tumours. The new edition of WHO Skin Blue books incorporates the most recent developments in skin tumours, including melanoma. This includes new categorisation based on recent genetic information and cliniopathological correlations. This classification will have significant impact of reporting and management of melanoma and melanocytic skin lesions.
These reference books are at an international standard for any medical professional or research professional. This publication has long been regarded by pathologists as the highest standard of reference for the diagnosis of tumours. It is an essential guide for evaluation, clinical trials and cancer studies.
This edition updates and discusses the significant changes to the classification of melanoma, based on the latest information from genetic and molecular studies. It also provides vital information on pathology, genealogy, prognosis and protection for each of the tumour types covered.
The 2021 Australasian Melanoma Conference (AMC2021) will held in Sydney, Australia.
The easing of COVID restrictions has meant the return of community events, and we recognise the generous support of our community fundraisers.
Melanoma patients and their carers are being urged to participate in a ground-breaking survey which will shape the future of melanoma treatment, research, support and funding in Australia.
We have been buoyed by the wonderful support for our Melanoma March campaign, and our mission to cover Australia in footprints continues into April!
There was a wonderful feeling of community support amongst the melanoma patients, families and friends at the WA Melanoma Community Form.
The Price family has decided to share their story to inspire Australians to support research into new melanoma treatments.
New research has provided evidence in favour of a structured skin surveillance program for high-risk melanoma patients.
Melanoma research saved Bert's life at 101 and now he wants to give back.
A new MIA online risk calculator for clinicians can determine the likelihood of thin melanoma spreading.
MIA has recently established a new division of our Clinical Trials Program which co-ordinates and manages investigator-led multi-centre trials.
Two young researchers from MIA and The University of Sydney awarded Cancer Institute NSW fellowships.
Aussies urged to leave their footprint on melanoma as efforts step up to save lives from the disease.
Olivia is using her Ninja star power to shine a spotlight on melanoma prevention - in memory of her dad.
Drug treatment before surgery, known as neoadjuvant therapy, is being hailed as one of the biggest breakthroughs in melanoma treatment since the advent of immunotherapy.
New research, led by MIA, has revealed that cancer patients treated with immunotherapy are not at a higher risk of developing severe COVID-19 infection compared to other cancer patients.
Stuart has advanced melanoma which is not responding to treatment. He has shared his story on ABC's 7:30 in the hope that others can escape the same fate.